High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 785-791

  Au, Karen ^a   Reed, George ^b   Curtis, Jeffrey R ^c   Kremer, Joel M ^d   Greenberg, Jeffrey D ^e   Strand, Vibeke ^f   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c The University of Alabama at Birmingham   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e NYU HOSPITAL FOR JOINT DISEASES   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTPATIENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT;

ADULT; AGED; AMBULATORY CARE; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; UNITED STATES;

EID: 79953314434     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.128637     Document Type: Article

References (32)

1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
2. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008;35:387-93. (Pubitemid 351374409)
3. Coyne P, Hamilton J, Heycock C, et al. Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 2007;34:1832-6. (Pubitemid 350067642)
4. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7. (Pubitemid 350100691)
5. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol 1982;11:81-6.
6. Hakoda M, Oiwa H, Kasagi F, et al. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis 2005;64:1451-5. (Pubitemid 41623856)
7. Mikuls TR, Saag KG, Criswell LA, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002;61:994-9. (Pubitemid 35221688)
8. Mutru O, Laakso M, Isomäki H, et al. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290:1797-9. (Pubitemid 15059221)
9. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, et al. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-53.
10. Riise T, Jacobsen BK, Gran JT, et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 2001;20:123-7.
11. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26 (5 Suppl 51):S35-61.
12. Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003;30:958-65. (Pubitemid 36529614)
13. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64 (Suppl 4):iv37-41.
14. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI):a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 (5 Suppl 39):S100-8.
15. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663-75. (Pubitemid 47163601)
16. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50. (Pubitemid 28465539)
17. Ranganath VK, Yoon J, Khanna D, et al. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 2007;66:1633-40. (Pubitemid 350205453)
18. Curtis JR, Patkar NM, Jain A, et al. Validity of physician-reported hospitalized infections in a US arthritis registry. Rheumatology (Oxford) 2009;48:1269-72.
19. Cleveland W. Visualizing data. Summit, NJ: Hobart Press 1993.
20. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001;57:120-5. (Pubitemid 32200145)
21. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135-7.
22. Hernández-Cruz B, Cardiel MH, Villa AR, et al. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998;25:1900-7. (Pubitemid 28459302)
23. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76. (Pubitemid 44204996)
24. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1157-60. (Pubitemid 47050621)
25. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
26. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
27. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81.
28. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64. (Pubitemid 47110375)
29. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69:380-6.
30. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
31. Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009;8:266-73.
32. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12. (Pubitemid 41612206)